The Call to Action proposes the following set of recommendations to prevent new infections; reduce deaths and adverse health outcomes; address disparities; coordinate action among federal, state, and local agencies and health systems; and ultimately reduce health care costs.
Specific Action Steps:
Review NASTAD’s and accompanying and share with staff and stakeholders in your jurisdiction
Identify opportunities to implement or expand activities geared towards the elimination of hepatitis C such as creating a state or local elimination plan
Focus on Prevention, Care, and Treatment for Priority Populations: The opioid epidemic is pervasive in rural, urban, and suburban America. HCV prevention, care, and treatment must be part of a comprehensive strategy to address the epidemic. People of color, Native Americans, homeless individuals, incarcerated populations, and people co-infected with HIV and HCV are disproportionately impacted by HCV and need to be engaged in efforts to end this epidemic.
Address the Opioid Epidemic and Drug User Health: The most cost effective strategy to prevent new HCV infections is to ensure a robust drug user health service infrastructure, with harm reduction strategies at the center, is in place in states and localities, and supported by federal resources.
Screening, Diagnosis, and Link to Care: Effort must be made to reach those most vulnerable for HCV by implementing screening and related services within the community, which often means outside of the clinical care setting. Improving the hepatitis C surveillance infrastructure, including making more resources available to support states and cities, is also critical.
Treatment and Follow Up: In response to the high initial cost of direct-acting antiviral HCV medications, many private and public health insurance payers responded by restricting access to these relatively new medications to those with the most advanced disease and who were not actively using drugs. With elimination as the goal, treatment must be accessible and affordable to everyone, and especially those living with HCV who have been subject to discriminatory, arbitrary sobriety requirements.
NASTAD’s vision is that new HCV infections in the United States are rare, and when they do occur, every person, regardless of substance use status, age, gender, race/ethnicity, sexual orientation, gender identity, disability, socio-economic status, incarceration status or geographic location, will have access to quality, affordable health care including comprehensive screening, care, and treatment leading to cure, without stigma and discrimination.
NASTAD believes that eliminating HCV should be a top public health priority. Unless we act boldly and urgently, we will continue to lose ground against the hepatitis C epidemic. We are hopeful that stakeholders at the national, state, and local levels will join our efforts to make the elimination of HCV in the U.S. a reality.
For more information on NASTAD’s , or hepatitis program and policy activities, please contact Chris Taylor, Senior Director, Hepatitis.
Please distribute to your networks. Thank you for your commitment to ending the hepatitis C epidemic!
An Academy Award winning director is seeking Hep C patients for a web documentary film about Hep C and the challenges related to living with the disease.
Consider signing on to the letter from the Hepatitis Appropriations Partnership (HAP) to the Office of Management and Budget regarding the President’s Fiscal Year 2017 budget.
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
New York has appropriated less than $1.2 million for an epidemic affecting more than 200,000 New Yorkers, which is causing increasing disability and death and healthcare costs.
NYC Council established the Viral Hepatitis Initiative in 2014, to fund community organizations to provide hepatitis B and C prevention, linkage to care and care services.
Senators Introduce Federal Legislation to Eliminate Hepatitis C On June 4, 2025, U.S. Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) introduced the Cure Hepatitis C Act of 2025, bipartisan legislation that would require the U.S. Department of Health and Human Services (...
We (hepfree.nyc) and selected third parties (7) collect personal information as specified in the privacy policy and use cookies or similar technologies for technical purposes and, with your consent, for functionality, experience, measurement and marketing (personalized ads).
You can freely give, deny, or withdraw your consent at any time by accessing the preferences panel. Denying consent may make related features unavailable.
Use the "Accept all" button to consent. Use the "Reject all" button to continue without accepting.
In this panel you can express preferences for the processing of your personal information. You may review and change your choices at any time.
NecessaryRequired for the site to function. Cannot be disabled.
FunctionalityEnables enhanced functionality and personalisation such as live chats and videos.
ExperienceAllows us to improve your experience based on how you use the site.
MeasurementHelps us measure traffic and analyse your behaviour to improve our service.
MarketingUsed to deliver personalised ads and marketing content based on your interests.
Sale of my personal informationUnder US state privacy laws you may opt out of the sale of your personal information.
Sharing of my personal informationControls whether your personal information is shared with third parties.
Processing for targeted advertisingAllows processing of your data to deliver targeted advertising across platforms.